Recommended standards for modern tuberculosis laboratory services in Europe

European Respiratory Journal

Volumn 28, Issue 5, 2006, Pages 903-909

  Drobniewski, F A ^a   Hoffner, S ^b   Rusch Gerdes, S ^c   Skenders, G ^d   Thomsen, V ^e  

^a HPA National Mycobacterium   (United Kingdom)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c RESEARCH CENTER BORSTEL   (Germany)

^d National TB Institute   (Latvia)

^e STATENS SERUM INSTITUT   (Denmark)

Author keywords

Culture; Guidelines; Microscopy; Molecular testing; Training; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ARTICLE; BACTERIUM CULTURE; CLINICAL COMPETENCE; DIAGNOSTIC ACCURACY; EUROPE; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; HUMAN; LABORATORY DIAGNOSIS; LABORATORY PERSONNEL; LABORATORY TEST; PRIORITY JOURNAL; QUALITY CONTROL; STAFF TRAINING; TUBERCULOSIS; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DRUG EFFECT; GENETICS; IN SERVICE TRAINING; INFECTION CONTROL; ISOLATION AND PURIFICATION; LABORATORY; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; STANDARD; WORLD HEALTH ORGANIZATION;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; HUMANS; INFECTION CONTROL; INSERVICE TRAINING; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 33847407942     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00084906     Document Type: Article

References (67)

1. Global tuberculosis control: surveillance, planning, financing. WHO report 2006. WHO/HTM/TB/2006.362. Geneva, World Health Organization, 2006.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement - global burden of tuberculosis: estimated incidence, prevalance, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
3. World Heath Organisation. Anti-tuberculosis drug resistance in the world: third global report/the WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance, 1999-2002. WHO/HTM/TB/ 2004.343. Geneva, World Health Organistion.
4. Drobniewski FA, Balabanova Y, Ruddy M, et al. Rifampinand multidrug-resistant tuberculosis in Russian civilians and prison inmates: dominance of the Beijing strain family. Emerg Infect Dis 2002; 8: 1320-1326.
5. Drobniewski FA, Balabanova Y, Nikolayevsky V, et al. Drug resistant tuberculosis, clinical virulence and the dominance of the Beijing strain family in Russia. JAMA 2005; 293: 2726-2731.
6. Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA. Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol 2002; 40: 1930-1937.
7. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Disease Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172: 1169-1227.
8. American Thoracic Society, Centers for Disease Control, Council of the Infectious Disease Society of America. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-1395.
9. Association of Public Health Laboratories. The future of TB laboratory services-a framework for integration, collaboration, leadership. Washington, DC, Association of Public Health Laboratories, 2004.
10. Drobniewski FA, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 2000, 3: 141-147.
11. Migliori GB, Raviglione MC, Schaberg T, et al. Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J 1999; 14: 978-992.
12. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, Royal College of Physicians, 2006.
13. National Tuberculosis Advisory Committee. Guidelines for Australian mycobacteriology laboratories. Commun Dis Intell 2006; 30: 116-128.
14. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
15. Pozniak AL, Miller RF, Lipman MC, et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med 2005; 6: Suppl. 2, 62-83.
16. Schwoebel V, Lambregts-Van Weez CSB, Moro ML, et al. Standardisation of tuberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group. Eur Respir J 2001; 16: 364-371.
17. Shinnick TM, Iademarco MF, Ridderhof JC. National plan for reliable tuberculosis laboratory services using a systems approach. Recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis Laboratory Services. MMWR Recomm Rep 2005; 54: 1-12.
18. World Health Organisation. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/tb/2006.361. www.who.int/tb. Geneva.
19. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). The Hague, Tuberculosis Coalition for Technical Assistance, 2006.
20. Tuberculosis Division International Union Against Tuberculosis and Lung Disease. Tuberculosis bacteriology-priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 2005; 9: 355-361.
21. World Health Organisation Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Geneva, Switzerland, 2006.
22. Woods GL, Long TA, Witebsky FG. Mycobacterial testing in clinical laboratories that participate in the College of American Pathologists Mycobacteriology Surveys: changes in practices based on responses to 1992, 1993, and 1995 questionnaires. Arch Pathol Lab Med 1996; 120: 429-435.
23. Richmond JY, Knudsen RC, Good RC. Biosafety in the clinical mycobacteriology laboratory. Clin Lab Med 1996; 16: 527-550.
24. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings - 2005. MMWR 2005; 54: 1-147.
25. Advisory Committee on Dangerous Pathogens UK Health and Safety Executive. The management, design and operation of microbiological containment laboratories. London, UK, 2001.
26. Health and Safety Executive. Health Services Advisory Committee. Safe working and the prevention of infection in clinical laboratories and similar facilities. London, UK, 2003.
27. Centers for Disease Control and Prevention. National Institutes of Health. Biosafety in microbiological and biomedical laboratories. HHS Publication No. (CDC) 99-8395. www.cdc.gov/od/ohs/biosfty/bmb14/ bmb14toc.htm. Washington, US Government Printing Office, 1999.
28. Ward-Cook K. Medical laboratory workforce trends and projections: what is past is prologue. Clin Leadersh Manag Rev 2002; 16: 364-369.
29. Figueroa-Munoz J, Palmer K, Poz MR, Blanc L, Bergstrom K, Raviglione M. The health workforce crisis in TB control: a report from high-burden countries. Hum Resour Health 2005; 3: 2.
30. Pascopella L, Kellam S, Ridderhof J, et al. Laboratory reporting of tuberculosis test results and patient treatment initiation in California. J Clin Microbiol 2004; 42: 4209-4213.
31. Ba F, Rieder HL. A comparison of fluorescence microscopy with the Ziehl-Neelsen technique in the examination of sputum for acid-fast bacilli. Int J Tuberc Lung Dis 1999; 3: 1101-1105.
32. Alcaide F, Benitez MA, Escriba JM, Martin R. Evaluation of the BACTEC MGIT 960 and the MB/BacT systems for recovery of mycobacteria from clinical specimens and for species identification by DNA AccuProbe. J Clin Microbiol 2000; 38: 398-401.
33. Brunello F, Favari F, Fontana R. Comparison of the MB/BacT and BACTEC 460 TB systems for recovery of mycobacteria from various clinical specimens. J Clin Microbiol 1999; 37: 1206-1209.
34. Hanna BA, Ebrahimzadeh A, Elliott LB, et al. Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. J Clin Microbiol 1999; 37: 748-752.
35. Piersimoni C, Scarparo C, Callegaro A, et al. Comparison of MB/Bact alert 3D system with radiometric BACTEC system and Lowenstein-Jensen medium for recovery and identification of mycobacteria from clinical specimens: a multicenter study. J Clin Microbiol 2001; 39: 651-657.
36. Pfyffer GE, Welscher HM, Kissling P, et al. Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol 1997; 35: 364-368.
37. Tortoli E, Cichero P, Piersimoni C, Simonetti MT, Gesu G, Nista D. Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study. J Clin Microbiol 1999; 37: 3578-3582.
38. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
39. World Health Organisation. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on anti-tuberculosis drug resistance surveillance. Geneva, Switzerland, 1997.
40. Irish C, Herbert J, Bennett D, et al. Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6. BMJ 1999; 318: 497-498.
41. Dewan P, Sosnovskaja A, Thomsen V, et al. High prevalence of drug-resistant tuberculosis, Republic of Lithuania, 2002. Int I Tuberc Lung Dis 2005; 9: 170-174.
42. Krüüner A, Hoffner SE, Sillastu H, et al. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001; 39: 3339-3345.
43. Skenders G. Multidrug-resistant tuberculosis detection, Latvia. Emerg Infect Dis 2005; 11: 1461-1463.
44. Mokrousov I, Otten T, Vyazovaya A, et al. PCR-based methodology for detecting multidrug-resistant strains of Mycobacterium tuberculosis Beijing family circulating in Russia. Eur J Clin Microbiol Infect Dis 2003; 22: 342-348.
45. Ruddy M, Y Balabanova Y, Graham C, et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 2005; 60: 130-135.
46. Kubica T, Agzamova R, Wright A, et al. The Beijing genotype is a major cause of drug-resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis 2005; 9: 646-653.
47. Controlled clinical trial of short-course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1; 1079-1084.
48. Controlled trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis, Second report. Second East African/British Medical Research Council Study. Am Rev Respir Dis 1976; 114: 471-475.
49. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112: 397-406.
50. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251.
51. Canetti G, Froman S, Grosset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-578.
52. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
53. Gingeras TR, Ghandour G, Wang E, et al. Simulataneous genotyping and species identification using hybridisation pattern recognition analysis of generic Mycobacterium DNA arrays. Genome Research 1998; 8: 435-448.
54. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence specific oligonucleotide probes. Proc Natl Acad Sci USA 1989; 86: 6230-6234.
55. Watterson SA, Wilson SM, Yates MD, Drobniewski FA. Comparison of three molecular assays for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. J Clin Microbiol 1998; 36: 1969-1673.
56. De Beenhouwer H, Lhiang Z, Jannes G, et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuberc Lung Dis 1995; 76: 425-430.
57. Drobniewski FA, Watterson SA, Wilson SM, Harris GS. A clinical, microbiological and economic analysis of a national UK service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis. J Med Microbiol 2000; 49: 271-278.
58. Mokrousov I, Filliol I, Legrand E, et al. Molecular characterization of multiple-drug-resistant Mycobacterium tuberculosis isolates from northwestern Russia and analysis of rifampin resistance using RNA/RNA mismatch analysis as compared to the line probe assay and sequencing of the rpoB gene. Res Microbiol 2002; 153: 213-219.
59. Nikolayevsky V, Brown T, Balabanova Y, Ruddy M, Fedorin I, Drobniewski F. Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J Clin Microbiol 2004; 42: 4498-4502.
60. Troesch A, Nguyen H, Miyada CG, et al. Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J Clin Microbiol 1999; 37: 49-55.
61. Eltringham IJ, Drobniewski FA, Mangan JA, Butcher PD, Wilson SM. Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of Mycobacterium tuberculosis. J Clin Microbiol 1999; 37: 3524-3527.
62. El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J Clin Microbiol 2001; 39: 4131-4137.
63. Piatek AS, Tyagi S, Pol AC, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol 1998; 16: 359-363.
64. Riska PF, Jacobs WR. The use of luciferase-reporter phage for antibiotic - susceptibility testing in mycobacteria. Methods Microbiol 1998; 101: 431-455.
65. Wilson SM, Al-Suwaidi Z, McNerney R, Porter J, Drobniewski FA. Evaluation of a new rapid bacteriophagebased method for the drug susceptibility testing Mycobacterium tuberculosis. Nature Medicine 1997; 3: 465-468.
66. Albert H, Trollip AP, Mole RJ, Hatch SJ, Blumberg L. Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaque TB-RIF, a manual phagebased test. Int J Tuberc Lung Dis 2002; 6: 523-528.
67. Sam IC, Drobniewski F, More P, Kemp M, Brown T. Mycobacterium tuberculosis and rifampin resistance, United Kingdom. Emerg Infect Dis 2006; 12: 752-759.